Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case-control analysis

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2410-2422

  Cotté, François Emery ^a   Mercier, Florence ^b   De Pouvourville, Gérard ^c  

^a INSERM   (France)

^b STAT PROCESS   (France)

^c ESSEC BUSINESS SCHOOL   (France)

Author keywords

adherence; compliance; fracture risk; osteoporosis; persistence

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FRAGILITY FRACTURE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY HEALTH CARE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG COSTS; FEMALE; FRACTURES, BONE; FRANCE; HUMANS; MEDICAL RECORDS, PROBLEM-ORIENTED; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS;

EID: 58649115590     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.019     Document Type: Article

References (45)

1. Lane N.E. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 194 Suppl 2 (2006) S3-S11
2. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 17 (2006) 1726-1733
3. Delmas P.D., and Fraser M. European Union challenges member states to fight the 'silent epidemic' of osteoporosis. Eurohealth. 4 (1998) 1-4
4. Lekkerkerker F., Kanis J.A., Alsayed N., et al., Group for the Respect of Ethics and Excellence in Science (GREES). Adherence to treatment of osteoporosis: A need for study. Osteoporos Int. 18 (2007) 1311-1317
5. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: Terminology and definitions. Value Health. 11 (2008) 44-47
6. World Health Organization. Adherence to long-term therapies: Evidence for action.
7. (June 16, 2008). http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf Accessed
8. Cramer J.A., Gold D.T., Silverman S.L., and Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 18 (2007) 1023-1031
9. Penning-van Beest F.J., Goettsch W.G., Erkens J.A., and Herings R.M. Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis. Clin Ther. 28 (2006) 236-242
10. Weycker D., Macarios D., Edelsberg J., and Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 18 (2007) 271-277
11. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 81 (2006) 1013-1022
12. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 15 (2004) 1003-1008
13. McCombs J.S., Thiebaud P., McLaughlin- Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 48 (2004) 271-287
14. Rabenda V., Mertens R., Fabri V., et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 19 (2008) 811-818
15. Silverman S.L., Gold D.T., and Cramer J.A. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J. 100 (2007) 1214-1218
16. Briot K., Trémollières F., Thomas T., Roux C., and Comité scientifique du GRIO. How long should patients take medications for postmenopausal osteoporosis?. Joint Bone Spine 74 (2007) 24-31
17. Neviaser A.S., Lane J.M., Lenart B.A., et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 22 (2008) 346-350
18. Gold D.T., Martin B.C., Frytak J.R., et al. A claims database analysis of persistence with alendronate therapy and fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin 23 (2007) 585-594
19. van den Boogaard C.H., Breekveldt- Postma N.S., Borggreve S.E., et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: A database analysis study. Curr Med Res Opin. 22 (2006) 1757-1764
20. Bouée S., Charlemagne A., Fagnani F., et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine. 71 (2004) 214-220
21. Cramer J.A., Lynch N.O., Gaudin A.F., et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 28 (2006) 1686-1694
22. Crochard A., El Hasnaoui A., Pouchain D., et al. Diagnostic indicators of restless legs syndrome in primary care consultations: The DESYR study. Mov Disord. 22 (2007) 791-797
23. Chassany O., Le-Jeunne P., Duracinsky M., et al. Discrepancies between patient-reported outcomes and clinician-reported outcomes in chronic venous disease, irritable bowel syndrome, and peripheral arterial occlusive disease. Value Health. 9 (2006) 39-46
24. Van Ganse E., Laforest L., Alemao E., et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 21 (2005) 1389-1399
25. Fagnani F., and German-Fattal M. Antibiotic prescribing patterns of French GPs for upper respiratory tract infections: Impact of fusafungine on rates of prescription of systemic antibiotics. Am J Respir Med. 2 (2003) 491-498
26. Black D.M., Thompson D.E., Bauer D.C., et al., FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. [published correction appears in J Clin Endocrinol Metab. 2001; 86:938]. J Clin Endocrinol Metab. 85 (2000) 4118-4124
27. Cummings S.R., and Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet. 359 (2002) 1761-1767
28. Peterson A.M., Nau D.P., Cramer J.A., et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 10 (2007) 3-12
29. Rosenbaum P., and Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 70 (1983) 41-55
30. Obuchowski N.A. ROC analysis. AJR Am J Roentgenol. 184 (2005) 364-372
31. Wells G., Cranney A., Peterson J., et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 23 (2008) CD004523
32. Wells G.A., Cranney A., Peterson J., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 23 (2008) CD001155
33. Nguyen N.D., Eisman J.A., and Nguyen T.V. Anti-hip fracture efficacy of bisphosphonates: A Bayesian analysis of clinical trials. J Bone Miner Res. 21 (2006) 340-349
34. O'Donnell S., Cranney A., Wells G.A., et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 18 (2006) CD005326
35. Vég A., Rosenqvist U., and Sarkadi A. Self-management profiles and metabolic outcomes in type 2 diabetes. J Adv Nurs. 56 (2006) 44-54
36. Htoon H.M., Peng L.L., and Huak C.Y. Assessment criteria for compliance with oral hygiene: Application of ROC analysis. Oral Health Prev Dent. 5 (2007) 83-88
37. Bisson G.P., Gross R., Bellamy S., et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 5 (2008) e109
38. Cuevas González M.J., Valín L.O., Pérez-Simón M.D., et al., HAART Adherence Working Group of the Province of Léon, Spain. A prospective study of adherence and virologic failure in HIV-infected patients: Role of a single determination of plasma levels of antiretroviral medications. J Int Assoc Physicians AIDS Care (Chic Ill). 6 (2007) 245-250
39. Brookhart M.A., Avorn J., Katz J.N., et al. Gaps in treatment among users of osteoporosis medications: The dynamics of noncompliance. Am J Med. 120 (2007) 251-256
40. Lindsay R., Silverman S.L., Cooper C., et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 285 (2001) 320-323
41. Rossini M., Bianchi G., Di Munno O., et al., Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 17 (2006) 914-921
42. Lespessailles E, Cotté FE, Roux C, et al. Prevalence and features of osteoporosis in the French general population: The INSTANT study. J Bone Spine. In press.
43. Bouée S., Lafuma A., Fagnani F., et al. Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int. 26 (2006) 1063-1072
44. Cotté F.E., Fautrel B., and De Pouvourville G. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making (June 19, 2008) [Epub ahead of print]
45. Boonen S., Vanderschueren D., Venken K., et al. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: Enhanced efficacy by enhanced compliance. J Intern Med. 264 (2008) 315-332